Global Biosimilar Testing Service Market Research Report 2023

Publication ID:

PB502234104

Publication Date:

February 16, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Biosimilar are the biological based products used for various use in healthcare industry. Biosimilar products are very helpful to the patients and also offer therapeutic options. Biosimilar have a unique properties, which is used to study the biological functions and structures complexity of the sample.
Highlights
The global Biosimilar Testing Service market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Biosimilar Testing Service is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Biosimilar Testing Service is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Biosimilar Testing Service in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Biosimilar Testing Service include Charles River Laboratories International, Merck, PPD, LAB Holdings, Eurofins Scientific, Intertek, SGS, Profacgen and Antibody Analytics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Testing Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Testing Service.
The Biosimilar Testing Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar Testing Service market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Testing Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Charles River Laboratories International
Merck
PPD
LAB Holdings
Eurofins Scientific
Intertek
SGS
Profacgen
Antibody Analytics
Kymos Pharma Services
Medicilon
Pacific BioLabs
Sartorius
Segment by Type
Pharmacokinetic Assay
Tiered Immunogenicity Testing
Others
Segment by Application
Hospitals
Pharmaceutical Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Testing Service companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Testing Service Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Pharmacokinetic Assay
1.2.3 Tiered Immunogenicity Testing
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biosimilar Testing Service Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Pharmaceutical Companies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Testing Service Market Perspective (2018-2029)
2.2 Biosimilar Testing Service Growth Trends by Region
2.2.1 Global Biosimilar Testing Service Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilar Testing Service Historic Market Size by Region (2018-2023)
2.2.3 Biosimilar Testing Service Forecasted Market Size by Region (2024-2029)
2.3 Biosimilar Testing Service Market Dynamics
2.3.1 Biosimilar Testing Service Industry Trends
2.3.2 Biosimilar Testing Service Market Drivers
2.3.3 Biosimilar Testing Service Market Challenges
2.3.4 Biosimilar Testing Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Testing Service Players by Revenue
3.1.1 Global Top Biosimilar Testing Service Players by Revenue (2018-2023)
3.1.2 Global Biosimilar Testing Service Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilar Testing Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Testing Service Revenue
3.4 Global Biosimilar Testing Service Market Concentration Ratio
3.4.1 Global Biosimilar Testing Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Testing Service Revenue in 2022
3.5 Biosimilar Testing Service Key Players Head office and Area Served
3.6 Key Players Biosimilar Testing Service Product Solution and Service
3.7 Date of Enter into Biosimilar Testing Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Testing Service Breakdown Data by Type
4.1 Global Biosimilar Testing Service Historic Market Size by Type (2018-2023)
4.2 Global Biosimilar Testing Service Forecasted Market Size by Type (2024-2029)
5 Biosimilar Testing Service Breakdown Data by Application
5.1 Global Biosimilar Testing Service Historic Market Size by Application (2018-2023)
5.2 Global Biosimilar Testing Service Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biosimilar Testing Service Market Size (2018-2029)
6.2 North America Biosimilar Testing Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biosimilar Testing Service Market Size by Country (2018-2023)
6.4 North America Biosimilar Testing Service Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Testing Service Market Size (2018-2029)
7.2 Europe Biosimilar Testing Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biosimilar Testing Service Market Size by Country (2018-2023)
7.4 Europe Biosimilar Testing Service Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Testing Service Market Size (2018-2029)
8.2 Asia-Pacific Biosimilar Testing Service Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biosimilar Testing Service Market Size by Region (2018-2023)
8.4 Asia-Pacific Biosimilar Testing Service Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar Testing Service Market Size (2018-2029)
9.2 Latin America Biosimilar Testing Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biosimilar Testing Service Market Size by Country (2018-2023)
9.4 Latin America Biosimilar Testing Service Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Testing Service Market Size (2018-2029)
10.2 Middle East & Africa Biosimilar Testing Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biosimilar Testing Service Market Size by Country (2018-2023)
10.4 Middle East & Africa Biosimilar Testing Service Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Charles River Laboratories International
11.1.1 Charles River Laboratories International Company Detail
11.1.2 Charles River Laboratories International Business Overview
11.1.3 Charles River Laboratories International Biosimilar Testing Service Introduction
11.1.4 Charles River Laboratories International Revenue in Biosimilar Testing Service Business (2018-2023)
11.1.5 Charles River Laboratories International Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Biosimilar Testing Service Introduction
11.2.4 Merck Revenue in Biosimilar Testing Service Business (2018-2023)
11.2.5 Merck Recent Development
11.3 PPD
11.3.1 PPD Company Detail
11.3.2 PPD Business Overview
11.3.3 PPD Biosimilar Testing Service Introduction
11.3.4 PPD Revenue in Biosimilar Testing Service Business (2018-2023)
11.3.5 PPD Recent Development
11.4 LAB Holdings
11.4.1 LAB Holdings Company Detail
11.4.2 LAB Holdings Business Overview
11.4.3 LAB Holdings Biosimilar Testing Service Introduction
11.4.4 LAB Holdings Revenue in Biosimilar Testing Service Business (2018-2023)
11.4.5 LAB Holdings Recent Development
11.5 Eurofins Scientific
11.5.1 Eurofins Scientific Company Detail
11.5.2 Eurofins Scientific Business Overview
11.5.3 Eurofins Scientific Biosimilar Testing Service Introduction
11.5.4 Eurofins Scientific Revenue in Biosimilar Testing Service Business (2018-2023)
11.5.5 Eurofins Scientific Recent Development
11.6 Intertek
11.6.1 Intertek Company Detail
11.6.2 Intertek Business Overview
11.6.3 Intertek Biosimilar Testing Service Introduction
11.6.4 Intertek Revenue in Biosimilar Testing Service Business (2018-2023)
11.6.5 Intertek Recent Development
11.7 SGS
11.7.1 SGS Company Detail
11.7.2 SGS Business Overview
11.7.3 SGS Biosimilar Testing Service Introduction
11.7.4 SGS Revenue in Biosimilar Testing Service Business (2018-2023)
11.7.5 SGS Recent Development
11.8 Profacgen
11.8.1 Profacgen Company Detail
11.8.2 Profacgen Business Overview
11.8.3 Profacgen Biosimilar Testing Service Introduction
11.8.4 Profacgen Revenue in Biosimilar Testing Service Business (2018-2023)
11.8.5 Profacgen Recent Development
11.9 Antibody Analytics
11.9.1 Antibody Analytics Company Detail
11.9.2 Antibody Analytics Business Overview
11.9.3 Antibody Analytics Biosimilar Testing Service Introduction
11.9.4 Antibody Analytics Revenue in Biosimilar Testing Service Business (2018-2023)
11.9.5 Antibody Analytics Recent Development
11.10 Kymos Pharma Services
11.10.1 Kymos Pharma Services Company Detail
11.10.2 Kymos Pharma Services Business Overview
11.10.3 Kymos Pharma Services Biosimilar Testing Service Introduction
11.10.4 Kymos Pharma Services Revenue in Biosimilar Testing Service Business (2018-2023)
11.10.5 Kymos Pharma Services Recent Development
11.11 Medicilon
11.11.1 Medicilon Company Detail
11.11.2 Medicilon Business Overview
11.11.3 Medicilon Biosimilar Testing Service Introduction
11.11.4 Medicilon Revenue in Biosimilar Testing Service Business (2018-2023)
11.11.5 Medicilon Recent Development
11.12 Pacific BioLabs
11.12.1 Pacific BioLabs Company Detail
11.12.2 Pacific BioLabs Business Overview
11.12.3 Pacific BioLabs Biosimilar Testing Service Introduction
11.12.4 Pacific BioLabs Revenue in Biosimilar Testing Service Business (2018-2023)
11.12.5 Pacific BioLabs Recent Development
11.13 Sartorius
11.13.1 Sartorius Company Detail
11.13.2 Sartorius Business Overview
11.13.3 Sartorius Biosimilar Testing Service Introduction
11.13.4 Sartorius Revenue in Biosimilar Testing Service Business (2018-2023)
11.13.5 Sartorius Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Charles River Laboratories International
Merck
PPD
LAB Holdings
Eurofins Scientific
Intertek
SGS
Profacgen
Antibody Analytics
Kymos Pharma Services
Medicilon
Pacific BioLabs
Sartorius

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂